Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Vertex (VRTX) delivered earnings and revenue surprises of 6.05% and 3.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging ...

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Finally, KBC Group NV raised its stake in Vertex by 46.1% during the 3rd quarter. KBC Group NV now owns 2,099 shares of the company’s stock worth $81,000 after acquiring an additional 662 shares ...

Downgrading Vertex to neutral due to limited upside at ... I had a price target of $46 when I wrote about VERX in August, and the stock price today is $49 (after the jump post 3Q24 results).

Bank of America reduced their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating on the stock in a research report on Monday, October 14th.

Vertex Energy ( (VTNRQ) ) just unveiled an announcement. Vertex Energy, Inc. announced a retention bonus agreement with their newly appointed ...